TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03670641
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
Study: NCT03670641
Drug: Lispro
Normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
Study: NCT02632708
Drug: AG-221
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02632708
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02632708
Drug: daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02632708
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02632708
Drug: mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02632708
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00344149
Drug: Rituximab (Mabthera)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
Study: NCT03483506
Drug: BI 1467335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT03483506
Drug: BI 1467335 (C-14) intravenous solution
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution
Study: NCT00032786
Drug: natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03555123
Drug: Simdax
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan2.5mg/ml
Study: NCT02929888
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01238107
Drug: MT-102
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BETA BLOCKER
Study: NCT01912378
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00652561
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
Study: NCT00369941
Drug: Comparator: efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
Study: NCT00369941
Drug: Comparator: Placebo to efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
Study: NCT02508935
Drug: XARTEMIS XR
Normalized name: Xartemis XR
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets
Study: NCT01724450
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
Study: NCT01920022
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day one of medical abortion
Study: NCT01920022
Drug: etonorgestrel
Normalized name: Etonogestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01137994
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
Study: NCT01137994
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxane chemotherapy
Study: NCT01137994
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxane chemotherapy
Study: NCT01137994
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinka alkaloid
Study: NCT02254434
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
Study: NCT00934687
Drug: clostridium botulinum toxin type A neurotoxin complex
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
Study: NCT03437070
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously per protocol on Day 1 for 21-day cycles.
Study: NCT03437070
Drug: Olaratumab
Normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously per protocol
Study: NCT00548470
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline 1-2 mg/day
Study: NCT02859142
Drug: Chantix
Normalized name: Chantix
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
Study: NCT02466685
Drug: JNJ-18038683
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-18038683 10-20 mg/day tablet for 8 weeks
Study: NCT03229200
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
Study: NCT02057887
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mcg Pegasys SC once weekly
Study: NCT03044626
Drug: Radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)
Study: NCT03044626
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240 mg fixed dose (q2w)
Study: NCT02061384
Drug: 13-cis retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accutane is used for the treatment of severe acne
Study: NCT02061384
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol is a form of vitamin D given twice daily (BID)
Study: NCT00786838
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
Study: NCT03018626
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab (375 mg/m2) given intravenously (IV) on day 0
Study: NCT03018626
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
Study: NCT03018626
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
Study: NCT03018626
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone (100 mg) given orally bid on days 1 through to 5.
Study: NCT03018626
Drug: Vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (2 mg/m2) given on days 1 and 5
Study: NCT03018626
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bleomycin (10 mg) given IV on days 1 and 5
Study: NCT01319643
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
Study: NCT01449591
Drug: BFH772 1% ointment
DrugBank: BFH772 (DB16035)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01449591
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04892758
Drug: Formoterol fumarate 10 mcg
Normalized name: formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
Study: NCT04892758
Drug: Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
Study: NCT00254254
Drug: Exenatide - Exenatide - Placebo
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
Study: NCT00254254
Drug: Exenatide - Placebo - Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
Study: NCT00254254
Drug: Placebo - Exenatide - Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
Study: NCT00035438
Drug: St. John's Wort
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00873795
Drug: aripiprazole , sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
Study: NCT04496596
Drug: Suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin is administered via IV infusion as a single dose of 3 mg/kg
Study: NCT03104335
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
Study: NCT01999413
Drug: OMEGAVEN
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML Study treatment induction phase
Study: NCT01999413
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AML Study treatment induction phase
Study: NCT01999413
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AML Study treatment induction phase
Study: NCT01227889
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
Study: NCT04192994
Drug: Intravitreal Antibiotic Injection
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal Antibiotic Injection
Study: NCT02613481
Drug: Poly-L-Lactic Acid (Sculptra) injection
Normalized name: L-Lactic acid
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
Study: NCT01529957
Drug: Nemonoxacin Malate Sodium Chloride
Normalized name: malate
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
Study: NCT01506739
Drug: Donepezil Hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
Study: NCT01506739
Drug: Donepezil Hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
Study: NCT01506739
Drug: Donepezil Hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
Study: NCT03071536
Drug: Furosemide Injection
Normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
Study: NCT03407196
Drug: Forxiga
Normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral antidiabetics
Study: NCT03910998
Drug: Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
Study: NCT00620308
Drug: CD-NP
Normalized name: CD-NP
DrugBank: Cenderitide (DB11777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
Study: NCT05321524
Drug: OCA 5mg
Normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets administered orally once daily.
Study: NCT02620553
Drug: Human Insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
Study: NCT01053026
Drug: olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1) Olmesartan treatment or (2) Life modification and exercise training
Study: NCT02872064
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
Study: NCT00277264
Drug: Tiotropium (Spiriva®)
Normalized name: tiotropium Inhalation Powder [Spiriva]
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080366
Drug: 1-Octanol
Normalized name: 1-octanol
DrugBank: Caprylic alcohol (DB12452)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01795222
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
Study: NCT02479412
Drug: 800 μg AZD7594 once daily
Normalized name: eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study: NCT02479412
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation as needed
Study: NCT02264067
Drug: Talsaclidine
Normalized name: Talsaclidine
DrugBank: Talsaclidine (DB12287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02536846
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
Study: NCT03022916
Drug: Nail Polish + Efinaconazole Solution
Normalized name: Efinaconazole
DrugBank: Efinaconazole (DB09040)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application of Jublia to the nail of one big toe on top of the nail polish
Study: NCT03022916
Drug: Base Coat + Nail Polish + Top Coat + Efinaconazole Solution
Normalized name: efinaconazole Topical Product
DrugBank: Efinaconazole (DB09040)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
Study: NCT03022916
Drug: Nail Polish + Top Coat + Efinaconazole Solution
Normalized name: efinaconazole Topical Product
DrugBank: Efinaconazole (DB09040)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
Study: NCT00003011
Drug: marimastat
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg PO BID
Study: NCT00401570
Drug: Volociximab
Normalized name: Volociximab
DrugBank: Volociximab (DB06647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
Study: NCT00401570
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
Study: NCT00783536
Drug: Etanercept + Methotrexate
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02020031
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00953043
Drug: lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
Study: NCT01113398
Drug: AMG 102
Normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
Study: NCT01113398
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
Study: NCT00418834
Drug: ezetimibe and atorvastatin
Normalized name: Ezetimibe and Atorvastatin Tablets
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
Study: NCT00418834
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
Study: NCT02242227
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no